 The monoclonal antibody ( mAb) market has changed rapidly in the past 5 years: it has doubled in size , becoming dominated by fully human molecules , launched bispecific molecules , and faced competition from biosimilars. We summarize the market in terms of therapeutic applications , type and structure of mAbs , dominant companies , manufacturing locations , and emerging markets.